Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High – Time to Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $221.97 and last traded at $222.6410, with a volume of 206466 shares trading hands. The stock had previously closed at $217.46.

Analyst Upgrades and Downgrades

KRYS has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Bank of America raised their target price on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Citigroup upped their price target on Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Trading Up 1.9%

The firm has a market capitalization of $6.43 billion, a P/E ratio of 33.28 and a beta of 0.48. The business has a 50 day moving average of $195.38 and a 200-day moving average of $161.38.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. On average, analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Institutional Trading of Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC raised its holdings in shares of Krystal Biotech by 4.4% in the third quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after purchasing an additional 117,777 shares during the last quarter. State Street Corp increased its stake in Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after buying an additional 128,639 shares during the last quarter. Soleus Capital Management L.P. lifted its position in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after buying an additional 481,200 shares in the last quarter. Braidwell LP lifted its position in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after buying an additional 327,067 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Krystal Biotech by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock worth $85,174,000 after buying an additional 7,194 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).